Job Title

Job ID :- e404b98c-d9ce-452e-b25d-f795e6789788OverviewMenarini Stemline US is looking for a dedicated and detail-oriented Human Resources specialist to join our team. This will be a full-time temporary position for 1 year start date TBD, 30-35 hours per week, fully remote. In this role, you will support the broader HR team in several initiatives, however, the main responsibilities center around onboarding, leave administration, producing and ensuring accurate data requests and other special projects requested by Total Rewards. It may be necessary to come into either the Bridgewater, NJ or New York, New York office as needed, no more than once a month. As a Human Resources specialist, you will collaborate closely with various departments to coordinate resources, address logistical needs, and assist employees with completion of all new hire items. Your exceptional communication skills will be vital in effectively communicating our company's culture, policies, and procedures to recruits, candidates new hires, and employees. Additionally, you will facilitate connections between new employees and their colleagues, promoting collaboration and a sense of belonging within our company. Additionally, this position requires that all terminated employees are properly accounted for in all of our systems as well as with equipment return and any outstanding items such as final expenses and pay items.As an ideal candidate, you will contribute to our company's growth and success by supporting the Human Resources team with a number of HR initiatives. If you are passionate about human resources and helping employees thrive, we invite you to join our team as a Human Resources Specialist.ResponsibilitiesONBOARDING:Coordinate background investigations through third party vendor if necessary.Coordinate with respective Executive Assistant(s) within the department that the new hire will join, what equipment and resources the new hire will need, and any systems the new hire will be entered into and/or may need access toCoordinate with the IT team and any other departments on equipment needsSchedule all day one sessions. Act as backup for new hire onboarding training where necessaryAdd new hire to all other employee portals as necessary(i.e., We People, Fidelity Investments, Plansource, and M-Learning)Create new hire announcementsProvide necessary information and resources to facilitate a successful transition for new employees and ensuring a smooth onboarding process.Serve as a point of contact for new hires and existing employees, addressing their questions and concernsFacilitate the completion of new hire paperwork, including benefits enrollment, and other necessary documentation.Monitor the progress and integration of new employees, identify any challenges, and provide support as neededOFFBOARDING:Assist with terminated employees in relation to last day needs, final pay, and return of equipmentTerminate employees in all systemsLEAVE ADMINISTRATION:Meet with all employees who will be going out on leave to explain Stemline leave process and procedures, including entitlements and vendor utilizationEnsure all leaves are accurately administered from start to finish, coordinate with payroll and other departments that all aspects of the leave are being coordinated and accounted for correctlyAssist employees with all leave applications and appropriate paperwork if necessaryReturn employee from leave into all related systems CONTRACTOR MANAGEMENT:Onboard new contactors, run background checks if necessaryCommunicate with managers when their contractor is due to expire and give renewal optionsMeet with the managers monthly to review the contractor listOff-board contractors DATA MAINTENANCE:Maintain and ensure that all employee data across Stemline systems is current and accurateConduct audits and run reports where necessaryAssist in the year-end processes (Open Enrollment/Year-end process), maintaining strict version controlWork on various Excel files to completionAssist with billing and invoices requests, work with Procurement and Accounts Payable to manage POu2019s and invoice requests Other Projects as assigned by Head of Total Rewards and Senior HR Generalist.QualificationsBA or AA degree in business administration, human resources or other related5 yearsu2019 experience in onboarding and HR best practices.Must be comfortable and experienced with working with highly sensitive and confidential data.Strong organizational and multi-tasking skills.Excellent communication skills.High-level attention to detail.Working knowledge of Google termediate to Advanced MS Word and Excel skills.Working knowledge of HRIS systems.Basic knowledge of labor laws. Hourly rate: $35-45 per hour. This position will be eligible for medical and other benefits. Please note--this position is classified as a corporate office position. In accordance with the New York employer convenience rule, Stemline will withhold New York state income taxes for all corporate office employees, regardless of whether these employees work in New York or remotely. Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran. Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions. The Company Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Groupu2019s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history. The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market. Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents. Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menariniu2019s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF). Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines. Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023. Menariniu2019s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. MSBu2019s CELLSEARCH Circulating Tumour Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods. Since 2021, MSB has offered in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1/HER2 biomarker and offer a minimally invasive approach to follow cancer patientu2019s therapeutic journey. In 2022, the company launched the CELLSEARCHu00ae Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies. Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management. It is an exciting time in the companyu2019s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemlineu2019s Oncology business.Apply for this job onlineShare on your newsfeedMinimum Salary: 35Maximum Salary: 45Salary Unit: Yearly